Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) are tyrosine kinases that mediate... more
Product information "Pacritinib"
FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) are tyrosine kinases that mediate cytokine signaling and are frequently mutated in cancers, particularly acute myeloid leukemia. Pacritinib is an inhibitor of both FLT3 and JAK2 (IC50s = 22 and 23 nM, respectively). It also blocks the activities of the FLT3 D835Y mutant, FLT3 with internal tandem duplications (ITDs), and JAK2 with a V617F substitution (IC50s = 6, 20-180, and 220 nM, respectively). Pacritinib also inhibits JAK1, JAK3, and TYK2 (IC50s = 1280, 520, and 50 nM, respectively). Pacritinib is orally bioavailable, inhibiting FLT3 and JAK2 signaling, tumor growth, and metastasis in xenografts in mice. It is synergistic with the histone deacetylase inhibitor pracinostat (also known as SB 939, Cay-10443), decreasing cell proliferation and inducing apoptosis in cells carrying either the JAK2 V617F mutation or FLT3 with ITDs, both in vitro and in vivo. Pacritinib has potential in resolving hematological malignancies.Formal Name: 11-[2-(1-pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16E,21,23-decaene. CAS Number: 937272-79-2. Synonyms: SB1518. Molecular Formula: C28H32N4O3. Formula Weight: 472.6. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: .5 mg/ml (slightly warmed). lambdamax: 285 nm. SMILES: C12=C(OCCN3CCCC3)C=CC(/N=C4N=CC=C(C5=CC=CC(COC/C=C/COC2)=C5)N/4)=C1. InChi Code: InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+. InChi Key: HWXVIOGONBBTBY-ONEGZZNKSA-N.
Keywords: | SB1518, 11-[2-(1-pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16E,21,23-decaene |
Supplier: | Cayman Chemical |
Supplier-Nr: | 16709 |
Properties
Application: | FLT3 / JAK2 inhibitor |
MW: | 472.6 D |
Formula: | C28H32N4O3 |
Purity: | >98% |
Format: | Crystalline Solid |
Database Information
CAS : | 937272-79-2| Matching products |
KEGG ID : | K05092 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | +20°C (International: -20°C) |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed